3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Precision H+,K+-ATPase Inhibition in Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a chemically defined, high-purity H+,K+-ATPase inhibitor (IC50 = 5.8 μM) validated for gastric acid secretion research. It is insoluble in water and ethanol but dissolves ≥17.27 mg/mL in DMSO, with optimal stability at -20°C. The compound exhibits robust antiulcer activity, inhibiting histamine-induced acid formation at IC50 = 0.16 μM. Its use is restricted to research settings and is not for diagnostic or therapeutic application. All product specifications are batch-verified by HPLC and NMR analyses (APExBIO; see also European Journal of Neuroscience).

Biological Rationale

Gastric acid secretion is regulated primarily by the gastric H+,K+-ATPase, or proton pump. Inhibition of this enzyme is a validated strategy for controlling gastric acidity and mitigating mucosal injury in peptic ulcer disease models (Kong et al., 2025). By targeting the final step in acid secretion, proton pump inhibitors (PPIs) disrupt downstream pathways contributing to acid-related disorders. The need for high-purity, selective inhibitors is underscored by their role in mechanistic studies and in vivo modeling of gastric pathologies. Recent research also implicates gastric acid modulation in gut–brain and neuroinflammatory axes, extending relevance beyond gastroenterology (Acridine-Orange: 2024).

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

This compound is a reversible, competitive inhibitor of gastric H+,K+-ATPase. It binds the catalytic subunit, blocking ATP-dependent proton exchange across parietal cell membranes. The specificity is supported by an IC50 of 5.8 μM for H+,K+-ATPase and 0.16 μM for histamine-induced acid formation, indicating higher potency in stimulated acid secretion settings. This selectivity minimizes off-target effects common to less-defined acid secretion inhibitors (OlodaterolMed: 2024). The mechanism aligns with established PPI pharmacology but offers advantages in experimental reproducibility due to its chemical purity (98% by HPLC/NMR).

Evidence & Benchmarks

• Demonstrates potent H+,K+-ATPase inhibition with an IC50 of 5.8 μM under in vitro assay conditions (pH 7.4, 25°C) (APExBIO).
• Inhibits histamine-induced gastric acid formation at an IC50 of 0.16 μM in isolated parietal cell systems (APExBIO).
• High chemical purity (≥98%) confirmed by HPLC and NMR, ensuring batch-to-batch reproducibility for research applications (OlodaterolMed: 2024).
• Solubility profile: insoluble in water/ethanol, ≥17.27 mg/mL in DMSO at room temperature (APExBIO).
• Enables reproducible modeling of gastric acid-related disorders in preclinical studies (CGS21680: 2024).
• Relevant to translational research linking gastric acid secretion and neuroinflammatory processes in gut–brain axis models (Kong et al., 2025).

Applications, Limits & Misconceptions

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is designed for scientific research into gastric acid secretion, proton pump inhibition pathways, and antiulcer activity studies. It is suitable for modeling peptic ulcer disease and studying the H+,K+-ATPase signaling axis. The compound is not approved for diagnostic, therapeutic, or in vivo human use, and long-term storage in solution is not recommended due to stability considerations. For research on gut–brain axis modulation, it provides a defined tool for probing the intersection of gastric and neuroinflammatory mechanisms, as discussed in Acridine-Orange (2024), which this article updates by providing new solubility and purity data.

Common Pitfalls or Misconceptions

• Not intended for human or veterinary therapeutic use—research only (APExBIO).
• Long-term solution storage (>1 week at RT) leads to compound degradation; always store at -20°C in solid form.
• Insoluble in aqueous and ethanol solvents, limiting application in water-based systems unless DMSO is used as a carrier.
• Does not inhibit non-gastric ATPases at relevant concentrations; not a pan-ATPase inhibitor.
• Comparisons to clinical PPIs (e.g., omeprazole) should account for differences in pharmacokinetics and in vivo bioavailability (ATP-Luminescent: 2024).

Workflow Integration & Parameters

This compound is best integrated into gastric acid secretion research workflows that require precise, high-purity H+,K+-ATPase inhibition. Optimal reconstitution occurs in DMSO at ≥17.27 mg/mL; avoid water or ethanol. For in vitro assays, use concentrations guided by the benchmark IC50 values. For in vivo animal models, dosing should be adjusted for solubility and pharmacokinetic profiles, referencing peer-reviewed protocols (CGS21680: 2024). The product is distributed by APExBIO under SKU: A2845 (product page), with batch-specific data available upon request.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide is a robust tool for probing gastric acid secretion and antiulcer mechanisms in research contexts. Its chemical definition and validated benchmarks support reproducible science, while its role in gut–brain and neuroinflammatory model systems is emerging. For further mechanistic and translational insights, see the analysis in Acridine-Orange (2024); this article extends those findings with updated purity and workflow data. Researchers should continue to observe best practices for compound handling, storage, and application in line with APExBIO's documentation and the evolving literature (Kong et al., 2025).